"Strengthening Communication with Shareholders"

Yuhan Corporation announced on the 20th that it would hold a non-deal roadshow (NDR) for domestic institutional investors over three days, starting from the previous day.


During this NDR, the company will prioritize an explanation of its core business competitiveness, including revenue growth and increased demand in its pharmaceutical business, as well as overseas business benefits resulting from the restructuring of the active pharmaceutical ingredient (API) industry supply chain. It will also share updates on the strengthening of the prescription base for Lazertinib, whose global expansion is now underway in earnest.


Yuhan Corporation Headquarters. Yuhan Corporation

Yuhan Corporation Headquarters. Yuhan Corporation

View original image

The company also plans to present strategies to accelerate its research and development (R&D) business, such as customized business development (BD) initiatives to maximize pipeline value, clinical trial joint research, and business model diversification using the Newco model.


Following this NDR, Yuhan Corporation intends to expand points of contact with individual investors by visiting securities firm PB centers across the nation, including those in the Seoul metropolitan area.



A Yuhan Corporation official commented, "Through this NDR, we aim to transparently share our growth strategies with investors," adding, "We will continue to enhance Yuhan Corporation's corporate value and reliability of information through various channels of communication."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing